Janssen Pharmaceuticals

What Janssen Pharmaceuticals does

Janssen Pharmaceuticals, Inc. is a wholly-owned pharmaceutical subsidiary of Johnson & Johnson (NYSE: JNJ) and operates as part of J&J's Innovative Medicine segment. The company's flagship commercial product is XARELTO (rivaroxaban), a direct oral anticoagulant (DOAC) that selectively blocks Factor Xa to reduce clotting risk. XARELTO holds the broadest label among DOACs in the US, covering six adult indications (nonvalvular atrial fibrillation stroke prevention, DVT/PE treatment and recurrence reduction, post-hip/knee replacement prophylaxis, hospital-associated clot prevention, CAD, and PAD) and is also the only DOAC approved for pediatric use from birth to 18 years, including post-Fontan procedure prophylaxis.

The business model is prescription pharmaceutical sales through retail pharmacies, PBMs, hospital systems, and mail-order channels, with patient access supported by the XARELTO withMe savings card, a 30-day trial offer, and the J&J Patient Assistance Program. Revenue mechanics depend on per-prescription volume rather than enterprise contracts, and pricing is not publicly disclosed. The company maintains a Medical Information Center in Titusville, NJ (its listed operating base) and operates through Janssen Pharmaceutica NV in Belgium for international licensing activities.

Beyond XARELTO, Janssen's pipeline and partnered programs include JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer co-developed with Nanobiotix for oncology (Phase 2 CONVERGE in NSCLC, Phase 3 NANORAY-312 in head and neck cancer); botaretigene sparoparvovec, a gene therapy in Phase III LUMEOS for X-linked retinitis pigmentosa with MeiraGTx; and multiple Phase 1-4 multiple myeloma studies. The company is not independently publicly traded and does not disclose standalone revenue, but its regulatory, distribution, and clinical evidence base position it as a major player in the US anticoagulant and broader cardiovascular/oncology markets.

Name

Janssen Pharmaceuticals

Legal name

Janssen Pharmaceuticals, Inc.

Website

https://xarelto-us.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Janssen Pharmaceuticals is a Johnson & Johnson subsidiary that markets XARELTO (rivaroxaban), the leading US direct oral anticoagulant, across six adult and two pediatric indications, with a growing pipeline in oncology and gene therapy via partnerships.

Ownership category

akta.pro rank

Product category

Anticoagulant Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Prescription pharmaceuticals
• Anticoagulant therapy
• Cardiovascular medicine
• Direct oral anticoagulants
• Thrombosis treatment

Headquarters

HQ city

Titusville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. XARELTO Pharmaceutical Sales: Prescription pharmaceutical product revenue from XARELTO (rivaroxaban), a direct oral anticoagulant marketed for multiple cardiovascular indications including atrial fibrillation, DVT, PE, CAD, PAD, and post-surgical prophylaxis. The product is distributed through retail pharmacies and healthcare providers via prescription.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Janssen Pharmaceuticals develops, manufactures, and markets prescription pharmaceutical products, with the commercial flagship being XARELTO (rivaroxaban), a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa. XARELTO is approved for stroke prevention in nonvalvular atrial fibrillation, treatment and prevention of DVT/PE, reduction of cardiovascular events in coronary artery disease (CAD) and peripheral artery disease (PAD), prevention of clots after orthopedic surgery, prevention of clots in hospitalized non-surgical patients, and pediatric DVT/PE treatment and post-Fontan clot prevention. The product is supplied as oral tablets and a 1 mg/mL oral suspension.

Product overview

Janssen Pharmaceuticals, a Johnson & Johnson company, markets XARELTO (rivaroxaban), a prescription blood thinner and direct oral anticoagulant (DOAC). XARELTO is the primary pharmaceutical product in the provided sources, offered in tablet and oral suspension forms for multiple adult and pediatric indications. The product portfolio includes the XARELTO medication itself along with the XARELTO withMe patient support program providing savings cards, trial offers, and cost assistance. XARELTO is indicated across six adult cardiovascular/thrombosis conditions and two pediatric uses, making it the most prescribed DOAC in the US with over 80 million prescriptions.

Differentiator

Problem solved

Functional benefit

Brands

• XARELTO withMe: Patient savings and support program for XARELTO medication
• JNJ-1900 (NBTXR3)
• Botaretigene sparoparvovec

Products and services

• XARELTO (rivaroxaban) tablets XARELTO tablets are a prescription direct oral anticoagulant (DOAC) that selectively blocks Factor Xa, marketed by Janssen Pharmaceuticals for stroke prevention in nonvalvular atrial fibrillation, treatment and prevention of DVT/PE, reduction of cardiovascular events in CAD/PAD when combined with low-dose aspirin, and prevention of clots after hip or knee replacement surgery in adults.
• XARELTO (rivaroxaban) 1 mg/mL oral suspension XARELTO oral suspension is a liquid formulation of rivaroxaban at 1 mg/mL designed for pediatric patients, with weight-based color-coded dosing guidance. It is the only DOAC with FDA approval for pediatric use from birth to 18 years for treating and reducing risk of recurrent DVT/PE, and the only DOAC indicated to help prevent blood clots in children with congenital heart disease after the Fontan procedure.
• XARELTO withMe patient support program XARELTO withMe is a patient access and adherence program operated through Janssen CarePath that helps eligible commercially insured patients pay as little as $10 per 90-day XARELTO fill, provides a free 30-day trial supply for qualifying new prescriptions, offers refill reminders and educational resources, and routes uninsured or underinsured patients to the Johnson & Johnson Patient Assistance Program for free medicine.

Quantifiable outcome

• Over 96% stroke-free rate in atrial fibrillation patients (3.8% stroke rate vs 4.3% for warfarin)
• +5 more outcomes

Named customers7 records

Segments7 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• NanobiotixcoreStrategic or Co-development Partner · 1 January 2023Global co-development and commercialization license agreement established in 2023 between Nanobiotix and Janssen Pharmaceutica NV (a Johnson & Johnson company) for JNJ-1900 (NBTXR3), a novel hafnium oxide nanoparticle radioenhancer. Johnson & Johnson is sponsoring the Phase 2 CONVERGE study for stage 3 inoperable non-small cell lung cancer and Phase 3 NANORAY-312 study for head and neck cancer. In October 2025, sponsorship and operational control of the Phase 3 head and neck cancer trial was transferred to Johnson & Johnson.
• MeiraGTxcoreStrategic or Co-development PartnerCollaboration for Botaretigene sparoparvovec, an investigational gene therapy for X-linked retinitis pigmentosa. MeiraGTx received a $50 million milestone payment in February 2024 following initiation of the extension study for the Phase III LUMEOS clinical trial. MeiraGTx is a biopharmaceutical company developing gene therapies for retinal diseases.
• Johnson & Johnson Private LimitedminorStrategic or Co-development PartnerMultiple Myeloma research collaboration. Between April 3-16, 2026, Johnson & Johnson Private Limited and Janssen Research & Development LLC each initiated new clinical studies in multiple myeloma across phases 1-4 as part of the broader pharmaceutical research portfolio.
• Odyssey TherapeuticsminorStrategic or Co-development PartnerCollaboration with Johnson & Johnson in autoimmune disease treatments. Odyssey Therapeutics is developing autoimmune disease treatments including ongoing trials and collaborations with Johnson & Johnson and Terray Therapeutics. J&J collaboration supports Odyssey's pipeline development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pfizer: Pfizer is the co-marketer of Eliquis (apixaban) with Bristol-Myers Squibb, the principal DOAC competitor to XARELTO. Both companies compete in the same cardiology/anticoagulant category with overlapping physician call points and payer negotiations.
• Daiichi Sankyo: Daiichi Sankyo markets Lixiana/Savaysa (edoxaban), another direct oral Factor Xa inhibitor approved for stroke prevention in AFib and treatment of DVT/PE. Directly competes in the same DOAC class as XARELTO across overlapping cardiovascular indications.
• Bristol-Myers Squibb: BMS co-markets Eliquis (apixaban) with Pfizer, the leading direct oral anticoagulant that has overtaken XARELTO in U.S. DOAC revenue and scripts. Direct head-to-head competitor in atrial fibrillation stroke prevention, DVT/PE treatment, and post-surgical prophylaxis.
• Boehringer Ingelheim: Boehringer Ingelheim markets Pradaxa (dabigatran), the first FDA-approved DOAC and a direct competitor to XARELTO in stroke prevention and DVT/PE treatment. Comparable private, research-driven pharmaceutical company with overlapping anticoagulant franchise.

Broad incumbents

• Bayer: Bayer is the joint developer and ex-U.S. commercializer of XARELTO with Janssen, while also independently operating a large cardiovascular and consumer health portfolio (including Aspirin Cardio). The co-development agreement makes Bayer both a partner and a strategic incumbent in the same therapeutic space.
• Sanofi: Sanofi operates a large cardiovascular and thrombosis franchise (including Plavix historically and Lovenox/Clexane enoxaparin) that competes in adjacent anticoagulant categories. A broad incumbent comparable to Janssen in therapeutic-area breadth and prescription-driven commercial model.
• Novartis: Novartis is a large branded pharmaceutical company with overlapping cardiovascular and specialty medicine portfolios, sharing the same prescription-pharma distribution model and prescriber channels as Janssen. A broad incumbent in the same therapeutic and competitive landscape.
• AstraZeneca: AstraZeneca markets Brilinta (ticagrelor) in the cardiovascular/thrombosis space and acquired the Factor Xa inhibitor portfolio via its Alexion/Portola acquisition, giving it a direct DOAC competitive position. A broad incumbent in cardiovascular and related specialty pharma categories.

Others

• Bayer (Aspirin Cardio): Dup-removed; Bayer already listed above as co-developer. If a separate low-dose aspirin comparator is needed, Bayer's Aspirin Cardio is a relevant OTC comparator specifically in the CAD/PAD combination therapy positioning where XARELTO+aspirin competes.

Emerging players

• Anthos Therapeutics: Anthos Therapeutics is developing abelacimab, a Factor XI inhibitor designed as a next-generation anticoagulant with potentially lower bleeding risk. An emerging player whose anticoagulant pipeline, if approved, would directly challenge the DOAC class (XARELTO, Eliquis, etc.) on safety grounds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Janssen Pharmaceuticals